Vanda Pharmaceuticals Inc.
Washington, DC
- UEI
- NG5JU1TQ3379
- CAGE
- 68U09
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 2200 Pennsylvania Ave NW #300e, Washington, DC 20037, USA
- Website
- vandapharma.com
- Founded
- 2003
- Employees
- 251-1K
- Estimated annual revenue
- $100M-$250M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | -$5,360 |
| FY2025 | $154,049 |
| FY2024 | $158,972 |
| FY2023 | $29,628 |
Contract vehicles
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Pharm - hetlioz | Veterans Integrated Service Network 20 (VHA) | $26,344 | |
| Hetlioz - bulk | Veterans Integrated Service Network 20 (VHA) | $131,068 | |
| Pharmaceutical | Veterans Integrated Service Network 20 (VHA) | $154,049 | |
| Hetlioz 20MG capsule | Veterans Integrated Service Network 20 (VHA) | $77,799 | |
| Tasimelteon 20MG cap (HETLIOZ) | Veterans Integrated Service Network 12 (VHA) | $32,891 |
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Harmony Biosciences LLC | Plymouth Meeting, PA | 325412 Pharmaceutical Preparation Manufacturing |
| Mirum Pharmaceuticals, Inc. | San Mateo, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Idorsia Pharmaceuticals US Inc. | Wayne, PA | 325412 Pharmaceutical Preparation Manufacturing |
| Biogen U.s. Corporation | Cambridge, MA | 325412 Pharmaceutical Preparation Manufacturing |
| Avadel CNS Pharmaceuticals, LLC | Chesterfield, MO | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Vanda Pharmaceuticals Inc., headquartered in Washington, DC, is a for-profit corporate entity registered in SAM.gov since 2011 and specializing in pharmaceutical manufacturing. The company is a global biopharmaceutical manufacturer primarily focused on developing and producing specialized pharmaceutical products, with a particular emphasis on HETLIOZ (tasimelteon), a medication used to treat Non-24-Hour Sleep-Wake Disorder in blind adults and patients with Smith-Magenis Syndrome. As a pharmaceutical manufacturer, Vanda provides specialized medical products to federal agencies, with a significant portion of its federal contract work concentrated within the U.S. Department of Veterans Affairs (VA).
Through its federal contract awards, Vanda has consistently provided pharmaceutical products, specifically HETLIOZ 20MG capsules, to various Veterans Integrated Service Networks (VISNs), including VISN 12 and VISN 20. The company's contract awards are not designated as set-asides and are primarily delivered through Delivery Order and Blanket Purchase Agreement (BPA) contracts under the Pharmaceuticals and Drugs GSA Schedule (FSS-61-IB). The contract values have ranged from approximately $32,000 to $171,234, with contract periods typically spanning one year. Each contract supports the VA's efforts to provide specialized pharmaceutical products to eligible veterans, addressing unique medical needs through targeted medication solutions.
Vanda holds multiple federal contract Indefinite Delivery Vehicles (IDVs), including a multiple-award Federal Supply Schedule contract with a $16,131,060 ceiling value through August 31, 2029, and two single-award Blanket Purchase Agreements with ceiling values of $3,753,465 and $3,069,780. These IDVs are primarily awarded by the VA National Acquisition Center and Veterans Integrated Service Networks, specifically covering drugs, pharmaceuticals, and hematology-related products. The contracts provide a streamlined procurement mechanism for VA agencies to order HETLIOZ, demonstrating Vanda's critical role as a key supplier of specialized pharmaceutical products to federal healthcare systems, particularly for veterans with specific medical conditions requiring targeted pharmaceutical interventions.
Quick answers
Is Vanda Pharmaceuticals Inc. registered in SAM.gov?
Yes. Vanda Pharmaceuticals Inc.'s SAM.gov registration is active through July 26, 2027.
What is Vanda Pharmaceuticals Inc.'s CAGE code?
Vanda Pharmaceuticals Inc.'s CAGE code is 68U09, and its Unique Entity ID (UEI) is NG5JU1TQ3379.
Which contract vehicles does Vanda Pharmaceuticals Inc. hold?
Vanda Pharmaceuticals Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Vanda Pharmaceuticals Inc. received in federal contracts?
Federal contracts obligated $154,049 to Vanda Pharmaceuticals Inc. in fiscal year 2025 and $337,290 in fiscal years 2023 through 2027.
What is Vanda Pharmaceuticals Inc.'s most recent federal award?
Vanda Pharmaceuticals Inc.'s most recent federal contract award is Pharm - hetlioz (36C26026F0025), from Veterans Integrated Service Network 20 (VHA), on October 1, 2025.
On GovTribe
See Vanda Pharmaceuticals Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors